Compass Therapeutics closes $132 mln Series A

Cambridge, Massachusetts-based Compass Therapeutics, a biotechnology company, has closed its $132 million Series A financing. OrbiMed Advisors led the round with participation from other investors that included F-Prime Capital, Cowen Healthcare Investments, Thiel Capital, Biomatics Capital, Ulysses Holdings, Borealis Ventures, Alexandria Venture Investments and Biomed Realty Ventures.

Source: Press Release